Case report reveals SARS-CoV-2 virus proteins in lymph node biopsy of a female with generalized sarcoidosis, suggesting possible post-COVID complications.
Aim: to present a clinical case of generalized sarcoidosis that developed after suffering a new coronavirus infection. Key points. Patient M., 45-years-old female, was hospitalized in the pulmonology department of the Clinic in October 2023 with complaints of shortness of breath that occurs with moderate physical exertion, sweating, increased fatigue. During the examination, the diagnosis was made: Main disease: Generalized sarcoidosis with lesions of the lungs, intrathoracic and peripheral lymph nodes, and spleen. Background disease: New coronavirus infection COVID-19 from January 2022. Prolonged postinfectious (new coronavirus infection) syndrome. Immunohistochemical examination of the biopsy of the supraclavicular lymph node in epithelioid cells, giant multinucleated cells in the cytoplasm revealed nucleocapsid and spike proteins of the SARS-CoV-2 virus. According to the treatment algorithms for sarcoidosis, 1st line therapy with systemic glucocorticosteroids was prescribed, followed by dose reduction and case monitoring. Conclusion. A clinical case of generalized sarcoidosis with verified virus persistence in sarcoid granuloma cells 1.5 years after an acute episode of COVID-19 is presented.
No takes yet. Share an insight, caveat, or question.
Bogacheva et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: